This site is intended for healthcare professionals outside the US.

In advanced, progressive pNET

AFINITOR maintains a clinical benefit in a diverse range of patients1

Diverse range of patient characteristics in RADIANT-3 study
pNET, pancreatic neuroendocrine tumor(s); WHO, World Health Organization.
  1. Yao JC, Shah MH, Ito T, et al; for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.